Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -34,541 | -20,059 | -1 | -19,567 |
| Depreciation Amortization | 10 | 5 | N/A | 5 |
| Accounts payable and accrued liabilities | 1,074 | 329 | N/A | 2,154 |
| Other Working Capital | 3,905 | 11,427 | N/A | 2,511 |
| Other Operating Activity | 3,663 | -34 | 0 | -1,001 |
| Operating Cash Flow | $-25,889 | $-8,332 | $-1 | $-15,898 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -8 | N/A | N/A | -52 |
| Investing Cash Flow | $-8 | $N/A | $N/A | $-52 |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | 7,907 | 5,000 | N/A | N/A |
| Debt Issued | 35,000 | N/A | N/A | N/A |
| Debt Repayment | -2,500 | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | N/A | 10,000 |
| Other Financing Activity | -2,503 | 303 | -177 | 18,053 |
| Financing Cash Flow | $37,904 | $5,303 | $-177 | $28,053 |
| Beginning Cash Position | 6,985 | 6,985 | 325 | N/A |
| End Cash Position | 18,992 | 3,956 | 148 | 12,103 |
| Net Cash Flow | $12,007 | $-3,029 | $-177 | $12,103 |
| Free Cash Flow | ||||
| Operating Cash Flow | -25,889 | -8,332 | -1 | -15,898 |
| Capital Expenditure | -8 | N/A | N/A | -52 |
| Free Cash Flow | -25,897 | -8,332 | -1 | -15,950 |